Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use
Antibiotic resistance in patients with cirrhosis continues to draw significant attention. With a propensity to frequent hospitalisations, patients with cirrhosis are subject to frequent antibiotic prescription. This increases their risk of developing resistance to one or more antimicrobial agents,...
Main Authors: | Rooshi Nathwani, Benjamin Mullish, David Kockerling, Alexander Cole, Nowlan Selvapatt, Ameet Dhar |
---|---|
Format: | Article |
Language: | English |
Published: |
European Medical Journal
2021-09-01
|
Series: | European Medical Journal |
Online Access: | https://www.emjreviews.com/hepatology/article/review-of-rifaximin-a-summary-of-the-current-evidence-and-benefits-beyond-licensed-use-j190321/ |
Similar Items
-
Diverticular Disease and Rifaximin: An Evidence-Based Review
by: Anna Piccin, et al.
Published: (2023-02-01) -
RIFAXIMIN TO TREAT OF GASTROINTESTINAL INFECTIONS
by: article editorial
Published: (2008-06-01) -
RIFAXIMIN TO TREAT OF GASTROINTESTINAL INFECTIONS
by: article editorial
Published: (2008-01-01) -
Impact of crystal polymorphism of rifaximin on dissolution behavior
by: Imen Toukabri, et al.
Published: (2024-03-01) -
Rifaximin: An Option for the Treatment of Irritable Bowel Syndrome
by: Muhammad Abdul Quddus , Arslan Shahzad , Rukhsana Munawar , Khawaja Tahir Maqbool , Amna Mansoor , Naveed Gani , Sheikh Muhammad Taqqi Anwer
Published: (2021-12-01)